Characterization and Outcomes of Luteal Phase Supportive Treatments in Infertile Women

This study aims to characterize and evaluate menstrual cycle length, luteal phase length, luteal spotting, and conception rates per cycle with or without luteal phase supportive treatments human chronic gonadotropin (hCG) and progesterone. We also aim to report frequency of luteal phase supportive treatments in women treating infertility.

Secondary inquiry and data entry of iNEST deidentified CrMS charts from the study period January 2006 to December 2016. Inclusion: Women ≥ 18 years old, desiring live birth, enrolled in the iNEST study. Exclusion: Incomplete or missing cycle parameter chart data.

Descriptive statistics for patient demographics and medication frequency. Generalized linear mixed model for assessment of menstrual cycle characteristics. The findings in this study help to further clarify existing data on LPD and luteal supportive medications. Menstrual cycle and luteal phase length were slightly longer with supportive medications; however, hCG produced the only statistically significant lengthened luteal phase. Spotting during the luteal phase was increased with hCG and progesterone respectively, though they were not statistically significant. Conception rates showed no difference with or without progesterone or hCG but failed to show statistical significance.